Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Daiichi Sankyo
Medtronic
Express Scripts
Chinese Patent Office
Queensland Health
Harvard Business School
Accenture
US Army
Dow

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,129,346

« Back to Dashboard

Which drugs does patent 8,129,346 protect, and when does it expire?


Patent 8,129,346 protects KYPROLIS and is included in one NDA. There has been one Paragraph IV challenge on Kyprolis.

This patent has sixty-nine patent family members in twenty-four countries.

Summary for Patent: 8,129,346

Title:Compounds for enzyme inhibition
Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Inventor(s): Smyth; Mark S. (San Mateo, CA), Laidig; Guy J. (Menlo Park, CA), Borchardt; Ronald T. (Lawrence, KS), Bunin; Barry A. (San Mateo, CA), Crews; Craig M. (New Haven, CT), Musser; John H. (San Carlos, CA)
Assignee: Onyx Therapeutics, Inc. (South San Francisco, CA)
Application Number:11/578,626
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-001Jul 20, 2012RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,129,346

PCT Information
PCT FiledApril 14, 2005PCT Application Number:PCT/US2005/012740
PCT Publication Date:November 10, 2005PCT Publication Number: WO2005/105827

Non-Orange Book Patents for Patent: 8,129,346

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,207,126Compounds for enzyme inhibition► Subscribe
7,232,818Compounds for enzyme inhibition► Subscribe
8,207,127Compounds for enzyme inhibition► Subscribe
8,207,297Compounds for enzyme inhibition► Subscribe
8,207,125Compounds for enzyme inhibition► Subscribe
8,198,270Compounds for proteasome enzyme inhibition► Subscribe
8,324,174Compounds for enzyme inhibition► Subscribe
8,207,124Compounds for enzyme inhibition► Subscribe
7,491,704Compounds for enzyme inhibition► Subscribe
7,417,042Compounds for enzyme inhibition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,129,346

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2012211349► Subscribe
BrazilPI0509879► Subscribe
BrazilPI0514102► Subscribe
Canada2562411► Subscribe
Canada2584515► Subscribe
Cyprus1117244► Subscribe
Canada2589765► Subscribe
China101006098► Subscribe
Germany602005025750► Subscribe
China101044157► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Colorcon
Dow
Baxter
AstraZeneca
McKesson
Merck
Cerilliant
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot